{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:35:29Z","timestamp":1789400129446,"version":"build-2803163510"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515010981"],"award-info":[{"award-number":["2020A1515010981"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010112","name":"Nanfang Hospital","doi-asserted-by":"publisher","award":["2018C013"],"award-info":[{"award-number":["2018C013"]}],"id":[{"id":"10.13039\/501100010112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional therapeutic options that will help only a limited percentage of HCC patients. Cancer immunotherapy has achieved dramatic advances in recent years and provides new opportunities to treat HCC. However, HCC has various etiologies and can evade the immune system through multiple mechanisms. With the rapid development of genetic engineering and synthetic biology, a variety of novel immunotherapies have been employed to treat advanced HCC, including immune checkpoint inhibitors, adoptive cell therapy, engineered cytokines, and therapeutic cancer vaccines. In this review, we summarize the current landscape and research progress of different immunotherapy strategies in the treatment of HCC. The challenges and opportunities of this research field are also discussed.<\/jats:p>","DOI":"10.3389\/fimmu.2021.765101","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T07:29:32Z","timestamp":1633332572000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":119,"title":["Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhuoyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meichuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29086","article-title":"AASLD Guidelines for the Treatment of Hepatocellular Carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B3","article-title":"The Survival Rate of Hepatocellular Carcinoma in Asian Countries: A\u00a0Systematic Review and Meta-Analysis","volume-title":"EXCLI J","author":"Hassanipour","year":"2020"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","article-title":"Cancer Statistics for the Year 2020: An Overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13505","article-title":"Comparative Analysis of Liver Functional Reserve During Lenvatinib and Sorafenib for Advanced Hepatocellular Carcinoma","volume":"50","author":"Terashima","year":"2020","journal-title":"Hepatol Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14817","article-title":"Lenvatinib Versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: An Inverse Probability of Treatment Weighting Analysis","volume":"41","author":"Casadei-Gardini","year":"2021","journal-title":"Liver Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/jso.26416","article-title":"The Evolving Landscape of Immunotherapy in Solid Tumors","volume":"123","author":"Keilson","year":"2021","journal-title":"J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102016","article-title":"Immunotherapy for Pancreatic Cancer: A 2020 Update","volume":"86","author":"Schizas","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02525","article-title":"Liver-Mediated Adaptive Immune Tolerance","volume":"10","author":"Zheng","year":"2019","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of Combination Therapy With Immune Checkpoint Inhibitors for Hepatocellular Carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103025","article-title":"Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives","volume":"12","author":"Federico","year":"2020","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.601240","article-title":"Immune Checkpoint Inhibitors in the Treatment of HCC","author":"Donisi","year":"1","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2019.12.002","article-title":"Immunotherapy for Hepatocellular Carcinoma","volume":"470","author":"Zongyi Y","year":"2020","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.4110\/in.2020.20.e11","article-title":"Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest","volume":"20","author":"Lee","year":"2020","journal-title":"Immune Netw"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102859","article-title":"Immunotherapy for Hepatocellular Carcinoma: A 2021 Update","volume":"12","author":"Kole","year":"2020","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in Immunotherapy for Hepatocellular Carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune Checkpoint Signaling and Cancer Immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 Ligands: From Discovery to Clinical Application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, non-Comparative, Phase 1\/2 Dose Escalation and Expansion Trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume-title":"J Clin Oncol","author":"Finn","year":"2020"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: A Randomized, Multi-Center Phase III Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1l) Treatment in Patients (Pts) With Advanced Hepatocellular Carcinoma (aHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.04.078","article-title":"LBA-3 CheckMate 459: Long-Term (Minimum Follow-Up 33.6 Months) Survival Outcomes With Nivolumab Versus Sorafenib as First-Line Treatment in Patients With","volume-title":"Ann Oncol","author":"Sangro","year":"2020"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1016\/j.annonc.2021.05.005","article-title":"O-1 Results From a Global Phase 2 Study of Tislelizumab, an Investigational PD-1 Antibody, in Patients With Unresectable Hepatocellular Carcinoma","volume":"32","author":"Ducreux","year":"2021","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2019.11.003","article-title":"Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy","volume":"41","author":"Liu","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2011.09.002","article-title":"Ipilimumab: A Novel Immunostimulatory Monoclonal Antibody for the Treatment of Cancer","volume":"65","author":"Graziani","year":"2012","journal-title":"Pharmacol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.05.002","article-title":"Impact of Tumour Microenvironment and Fc Receptors on the Activity of Immunomodulatory Antibodies","volume":"35","author":"Furness","year":"2014","journal-title":"Trends Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A Clinical Trial of CTLA-4 Blockade With Tremelimumab in Patients With Hepatocellular Carcinoma and Chronic Hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-018-0011-0","article-title":"A Reappraisal of CTLA-4 Checkpoint Blockade in Cancer Immunotherapy","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25777","article-title":"Tim-3\/Galectin-9 Signaling Pathway Mediates T-Cell Dysfunction and Predicts Poor Prognosis in Patients With Hepatitis B Virus-Associated Hepatocellular Carcinoma","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344392","article-title":"Enhanced Suppressor Function of TIM-3+FoxP3+ Regulatory T Cells","volume":"44","author":"Gautron","year":"2014","journal-title":"Eur J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 Comes of Age as an Inhibitory Receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-Like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an Immune Suppressor and Potential Target for Normalization Cancer Immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.14169","article-title":"Siglec-15 Promotes the Migration of Liver Cancer Cells by Repressing Lysosomal Degradation of CD44","volume":"595","author":"Liu","year":"2021","journal-title":"FEBS Lett"},{"key":"B36","article-title":"Immune Checkpoint Targeting TIGIT in Hepatocellular Carcinoma","volume":"12","author":"Zheng","year":"2020","journal-title":"Am J Transl Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The Surface Protein TIGIT Suppresses T Cell Activation by Promoting the Generation of Mature Immunoregulatory Dendritic Cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in Combination With Ablation in Patients With Advanced Hepatocellular Carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28372","article-title":"Combination of Radiofrequency Ablation and Sequential Cellular Immunotherapy Improves Progression-Free Survival for Patients With Hepatocellular Carcinoma","volume":"134","author":"Cui","year":"2014","journal-title":"Int J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S304857","article-title":"Camrelizumab Combined With FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib\/II Study","volume":"15","author":"Li","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific Monoclonal Antibodies for Targeted Immunotherapy of Solid Tumors: Recent Advances and Clinical Trials","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canlet.2017.04.013","article-title":"Immunotherapy of Hepatocellular Carcinoma Using Chimeric Antigen Receptors and Bispecific Antibodies","volume":"399","author":"Hoseini","year":"2017","journal-title":"Cancer Lett"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12011","article-title":"The Activity of \u03b3\u03b4 T Cells Against Paediatric Liver Tumour Cells and Spheroids in Cell Culture","volume":"33","author":"Hoh","year":"2013","journal-title":"Liver Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000349","article-title":"Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma","volume":"44","author":"Yu","year":"2021","journal-title":"J Immunother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms161126037","article-title":"TriFabs\u2014Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery","volume":"16","author":"Mayer","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e20200377","DOI":"10.1084\/jem.20200377","article-title":"Adoptive Cell Therapy: Living Drugs Against Cancer","volume":"217","author":"Laskowski","year":"2020","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1673129","article-title":"The Promise of Adoptive Cellular Immunotherapies in Hepatocellular Carcinoma","volume":"9","author":"Hendrickson","year":"2020","journal-title":"Oncoimmunology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00774","article-title":"Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy","author":"Gao","year":"1","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v10.i8.1146","article-title":"Autologous Cytokine-Induced Killer Cell Therapy in Clinical Trial Phase I is Safe in Patients With Primary Hepatocellular Carcinoma","volume-title":"World J Gastroenterol","author":"Shi","year":"2004"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02654-4","article-title":"Adoptive Immunotherapy to Lower Postsurgical Recurrence Rates of Hepatocellular Carcinoma: A Randomised Trial","volume":"356","author":"Takayama","year":"2000","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29827","article-title":"Ten-Year Update of the International Registry on Cytokine-Induced Killer Cells in Cancer Immunotherapy","volume":"235","author":"Zhang","year":"2020","journal-title":"J Cell Physiol"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v19.i19.2956","article-title":"Intraperitoneal Perfusion of Cytokine-Induced Killer Cells With Local Hyperthermia for Advanced Hepatocellular Carcinoma","volume-title":"World J Gastroenterol","author":"Wang","year":"2013"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.07.010","article-title":"Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma Patients After Curative Resection, a Systematic Review and Meta-Analysis","volume":"48","author":"Wang","year":"2016","journal-title":"Dig Liver Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-Infiltrating Lymphocytes in the Immunotherapy Era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-1759(87)80018-2","article-title":"Expansion of Human Tumor Infiltrating Lymphocytes for Use in Immunotherapy Trials","volume":"102","author":"Topalian","year":"1987","journal-title":"J Immunol Methods"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1258\/ebm.2011.011007","article-title":"Tumor-Infiltrating Immune Cells and Prognosis: The Potential Link Between Conventional Cancer Therapy and Immunity","volume":"236","author":"Jochems","year":"2011","journal-title":"Exp Biol Med (Maywood)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270214","article-title":"Clinicopathological Study on Hepatocellular Carcinoma With Lymphocytic Infiltration","volume":"27","author":"Wada","year":"1998","journal-title":"Hepatology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0053","article-title":"T-Cell-Associated Immunotherapy: A Promising Strategy for the Treatment of Hepatocellular Carcinoma","volume":"9","author":"Ma","year":"2017","journal-title":"Immunotherapy"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5463","article-title":"A Phase I Clinical Trial Utilizing Autologous Tumor-Infiltrating Lymphocytes in Patients With Primary Hepatocellular Carcinoma","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"B64","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41587-021-00929-0","article-title":"First CAR-T Therapy to Target BCMA Gets FDA Nod","volume":"39","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors","volume":"26","author":"Fuc\u00e0","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T Cell Immunotherapy for Human Cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2016.128","article-title":"CAR T-Cell Therapy of Solid Tumors","volume":"95","author":"Yong","year":"2017","journal-title":"Immunol Cell Biol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/med.21455","article-title":"Glypican-3: A Promising Biomarker for Hepatocellular Carcinoma Diagnosis and Treatment","volume":"38","author":"Zhou","year":"2018","journal-title":"Med Res Rev"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1170","article-title":"Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma","volume":"20","author":"Gao","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920910347","article-title":"Split Chimeric Antigen Receptor-Modified T Cells Targeting Glypican-3 Suppress Hepatocellular Carcinoma Growth With Reduced Cytokine Release","volume":"12","author":"Liu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00690","article-title":"Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma","volume":"7","author":"Jiang","year":"2016","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2013.09.003","article-title":"Alpha-Fetoprotein, a Fascinating Protein and Biomarker in Neurology","volume":"18","author":"Schieving","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1203","article-title":"Targeting Alpha-Fetoprotein (AFP)-MHC Complex With CAR T-Cell Therapy for Liver Cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0306068101","article-title":"Hepatocyte Growth Factor\/C-Met Signaling Pathway is Required for Efficient Liver Regeneration and Repair","volume":"101","author":"Huh","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.546586","article-title":"Bispecific C-Met\/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Front Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00562","article-title":"Editorial: Emerging Concepts on the NKG2D Receptor-Ligand Axis in Health and Diseases","volume":"11","author":"Guerra","year":"2020","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0026","article-title":"Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-020-01647-2","article-title":"CD147 Promotes Collective Invasion Through Cathepsin B in Hepatocellular Carcinoma","volume":"39","author":"Wang","year":"2020","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00233","article-title":"Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3724\/SP.J.1008.2014.01177","article-title":"Specific Cytotoxicity of MUC1 Chimeric Antigen Receptor-Engineered Jurkat T Cells Against Hepatocellular Carcinoma","volume":"35","author":"Ma","year":"2014","journal-title":"Acad J Second Military Med Univ"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jons.2017.04.002","article-title":"EpCAM as a Novel Therapeutic Target for Hepatocellular Carcinoma","volume":"3","author":"S","year":"2017","journal-title":"J Oncol Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e1440169","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-Directed CAR T Cells for Advanced Metastasis Malignancies: A Phase I Trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/15384047.2021.1916381","article-title":"The Role of CD133 in Hepatocellular Carcinoma","volume":"22","author":"Liu","year":"2021","journal-title":"Cancer Biol Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and Biomarker Analysis of CD133-Directed CAR T Cells in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2013.9","article-title":"NK Cells in Immunotolerant Organs","volume":"10","author":"Sun","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3390\/cells10061332","article-title":"Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches","volume":"10","author":"Kalathil","year":"2021","journal-title":"Cells"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100009","article-title":"CAR NK Cell Therapy for T Follicular Helper Cells","volume":"1","author":"King","year":"2020","journal-title":"Cell Rep Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of Anti-CD147 Chimeric Antigen Receptors Targeting Hepatocellular Carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2017.08.003","article-title":"Retroviral Gene Transfer Into Primary Human NK Cells Activated by IL-2 and K562 Feeder Cells Expressing Membrane-Bound IL-21","volume":"450","author":"Streltsova","year":"2017","journal-title":"J Immunol Methods"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxab052","article-title":"Engineering Strategies for Broad Application of TCR-T and CAR-T Cell Therapies","author":"Watanabe","year":"2021","journal-title":"Int Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1006613","article-title":"Clinical Practice. Chronic Hepatitis C Infection","volume":"364","author":"Rosen","year":"2011","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00262-016-1800-2","article-title":"TCR Gene-Modified T Cells can Efficiently Treat Established Hepatitis C-Associated Hepatocellular Carcinoma Tumors","volume":"65","author":"Spear","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering Virus-Specific T Cells That Target HBV Infected Hepatocytes and Hepatocellular Carcinoma Cell Lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J Hepatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC Metastases With Autologous T Cell Receptor Redirected T Cells, Targeting HBsAg in a Liver Transplant Patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30477","article-title":"Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer","volume":"69","author":"Docta","year":"2019","journal-title":"Hepatology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29844","article-title":"Identification of \u03b1-Fetoprotein-Specific T-Cell Receptors for Hepatocellular Carcinoma Immunotherapy","volume":"68","author":"Zhu","year":"2018","journal-title":"Hepatology"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.055","article-title":"T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice","volume":"149","author":"Dargel","year":"2015","journal-title":"Gastroenterology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21203","article-title":"Cytotoxic T Cell Responses to Human Telomerase Reverse Transcriptase in Patients With Hepatocellular Carcinoma","volume":"43","author":"Mizukoshi","year":"2006","journal-title":"Hepatology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.131","article-title":"Towards Personalized, Tumour-Specific, Therapeutic Vaccines for Cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e192589","DOI":"10.1001\/jamanetworkopen.2019.2589","article-title":"Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer","volume":"2","author":"Caram","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1053\/j.gastro.2017.02.001","article-title":"Association Between High-Avidity T-Cell Receptors, Induced by \u03b1-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma","volume":"152","author":"Nakagawa","year":"2017","journal-title":"Gastroenterology"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e1129483","DOI":"10.1080\/2162402X.2015.1129483","article-title":"Phase II Study of the GPC3-Derived Peptide Vaccine as an Adjuvant Therapy for Hepatocellular Carcinoma Patients","volume":"5","author":"Sawada","year":"2016","journal-title":"Oncoimmunology"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31502","article-title":"Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies","volume":"73","author":"Lu","year":"2021","journal-title":"Hepatology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.08.020","article-title":"Phase I Trial of Multidrug Resistance-Associated Protein 3-Derived Peptide in Patients With Hepatocellular Carcinoma","volume":"369","author":"Mizukoshi","year":"2015","journal-title":"Cancer Lett"},{"key":"B110","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.canlet.2015.04.031","article-title":"Immunological Features of T Cells Induced by Human Telomerase Reverse Transcriptase-Derived Peptides in Patients With Hepatocellular Carcinoma","volume":"364","author":"Mizukoshi","year":"2015","journal-title":"Cancer Lett"},{"key":"B111","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2796.2010.02317.x","article-title":"Dendritic Cells and Immunity Against Cancer","volume":"269","author":"Palucka","year":"2011","journal-title":"J Intern Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-002-0360-9","article-title":"A Phase I Study of Autologous Dendritic Cell-Based Immunotherapy for Patients With Unresectable Primary Liver Cancer","volume":"52","author":"Iwashita","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22626","article-title":"A Phase II Study of Adoptive Immunotherapy Using Dendritic Cells Pulsed With Tumor Lysate in Patients With Hepatocellular Carcinoma","volume":"49","author":"Palmer","year":"2009","journal-title":"Hepatology"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24882","article-title":"Enhancement of Tumor-Specific T-Cell Responses by Transcatheter Arterial Embolization With Dendritic Cell Infusion for Hepatocellular Carcinoma","volume":"126","author":"Mizukoshi","year":"2010","journal-title":"Int J Cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13046-021-01968-w","article-title":"Advances in Drug Development for Hepatocellular Carcinoma: Clinical Trials and Potential Therapeutic Targets","volume":"40","author":"Luo","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.276","article-title":"The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers","volume":"20","author":"Parato","year":"2012","journal-title":"Mol Ther"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089","article-title":"Randomized Dose-Finding Clinical Trial of Oncolytic Immunotherapeutic Vaccinia JX-594 in Liver Cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-Based Oncolytic Immunotherapy Pexastimogene Devacirepvec in Patients With Advanced Hepatocellular Carcinoma After Sorafenib Failure: A Randomized Multicenter Phase IIb Trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"Oncoimmunology"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1698-0","article-title":"Novel Metronomic Chemotherapy and Cancer Vaccine Combinatorial Strategy for Hepatocellular Carcinoma in a Mouse Model","volume":"64","author":"Tagliamonte","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0588","article-title":"Cancer Vaccines: Moving Beyond Current Paradigms","volume":"13","author":"Schlom","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"a033704","DOI":"10.1101\/cshperspect.a028829","article-title":"Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name","volume":"10","author":"Finn","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-med-042617-101816","article-title":"Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines","volume":"70","author":"Vormehr","year":"2019","journal-title":"Annu Rev Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in Cancer Immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B124","article-title":"Recombinant Alpha-2b-Interferon in Therapy of Previously Untreated Hairy Cell Leukemia: Long-Term Follow-Up Results of Study by Cancer and Leukemia Group B","volume":"9","author":"Rai","year":"1995","journal-title":"Leukemia"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2014.386","article-title":"Adjuvant Interferon for Early or Late Recurrence of Hepatocellular Carcinoma and Mortality From Hepatocellular Carcinoma Following Curative Treatment: A Meta-Analysis With Comparison of Different Types of Hepatitis","volume":"2","author":"Zhang","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e11295","DOI":"10.1097\/md.0000000000011295","article-title":"Adjuvant Pegylated Interferon Therapy Improves the Survival Outcomes in Patients With Hepatitis-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis","volume":"97","author":"Wu","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B127","doi-asserted-by":"publisher","first-page":"e11565","DOI":"10.7759\/cureus.11565","article-title":"Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy","volume":"12","author":"Fatima","year":"2020","journal-title":"Cureus"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.422","article-title":"Therapy of Primary and Metastatic Liver Cancer by Human iPS Cell-Derived Myeloid Cells Producing Interferon-\u03b2","volume":"24","author":"Sakisaka","year":"2017","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.05.049","article-title":"Endolymphatic Immunotherapy in Inoperable Hepatocellular Carcinoma","volume":"40","author":"Bertelli","year":"2008","journal-title":"Transplant Proc"},{"key":"B130","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni.2691","article-title":"Immune Surveillance by the Liver","volume":"14","author":"Jenne","year":"2013","journal-title":"Nat Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0044-z","article-title":"The Immunology of Hepatocellular Carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/hep.31416","article-title":"Liver Cancer Immunity","author":"Rizvi","year":"2021","journal-title":"Hepatology"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1749593","article-title":"Nivolumab for the Treatment of Hepatocellular Carcinoma","volume":"20","author":"Chiew Woon","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B134","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-Omics Prediction of Immune-Related Adverse Events During Checkpoint Immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat Commun"},{"key":"B135","doi-asserted-by":"publisher","first-page":"eaam7543","DOI":"10.1126\/scitranslmed.aam7543","article-title":"PD-L1 Genetic Overexpression or Pharmacological Restoration in Hematopoietic Stem and Progenitor Cells Reverses Autoimmune Diabetes","volume":"9","author":"Ben Nasr","year":"2017","journal-title":"Sci Transl Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/j.annonc.2021.05.142","article-title":"P-87 Real-World Data of Nivolumab in Advanced Hepatocellular Carcinoma: A Multi-Centric and Retrospective Study","volume":"32","author":"Sardinha","year":"2021","journal-title":"Ann Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4200","article-title":"Eradication of Large Established Tumors in Mice by Combination Immunotherapy That Engages Innate and Adaptive Immune Responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.765101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:40:53Z","timestamp":1673397653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.765101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":137,"alternative-id":["10.3389\/fimmu.2021.765101"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.765101","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,4]]},"article-number":"765101"}}